SLU-PP-332 500 mcg 60 capsules

SLU-PP-332 500 mcg – 60 capsules of an ERR pan-agonist research reagent

Research reagent for laboratory use only. Not for human or veterinary use, diagnostic, or therapeutic purposes.

SLU-PP-332 is a small-molecule research compound described in the literature as a synthetic pan-agonist of estrogen-related receptors: ERR alpha, ERR beta and ERR gamma. These nuclear receptors regulate transcriptional programs associated with mitochondrial biogenesis, oxidative metabolism and energy expenditure.

One-Peptides SLU-PP-332 500 mcg is supplied as a capsule-format research reagent containing 500 mcg per package in 60 capsules, approximately 8.3 mcg per capsule. The product is intended for laboratory research only and is documented with HPLC purity testing, MS identity confirmation and batch-level COA documentation.

What is SLU-PP-332 – pharmacological class

SLU-PP-332 belongs to the experimental class of ERR pan-agonists. ERRs are orphan nuclear receptors that coordinate transcriptional programs involved in mitochondrial oxidative capacity, skeletal-muscle energy metabolism and adaptive responses associated with exercise-like signaling.

The compound is often discussed in the context of exercise mimetics, a research category that includes compounds designed to reproduce selected molecular signatures of exercise without physical training. This does not mean it replaces exercise in humans; the term refers to experimental pathways and animal-model outcomes.

Reagent characteristics

Mechanism of action in mouse research

In mouse studies, SLU-PP-332 has been reported to induce an ERR alpha-dependent acute aerobic-exercise-like response and to enhance exercise capacity. The mechanistic focus is the ERR-PGC-1 alpha axis, which is involved in mitochondrial biogenesis, oxidative phosphorylation and skeletal-muscle endurance adaptation.

ERR agonism is expected to affect transcriptional regulation rather than acting as a direct stimulant. In experimental models, this places SLU-PP-332 in a different category from sympathomimetic stimulants or simple thermogenic agents. The central research question is whether selective nuclear-receptor activation can reproduce parts of the molecular exercise program.

ACS Chemical Biology 2023 and JPET 2024 – experimental context

The initial SLU-PP-332 publication in ACS Chemical Biology described a synthetic ERR alpha/beta/gamma agonist that induced an ERR alpha-dependent exercise-like response and enhanced exercise capacity in mice. The later Journal of Pharmacology and Experimental Therapeutics work discussed a synthetic ERR agonist in the context of metabolic-syndrome models.

These data are experimental and preclinical. They do not establish SLU-PP-332 as a medicine, food product or human-performance product. They provide a mechanistic framework for laboratory research on ERR signaling, mitochondrial metabolism and exercise-mimetic pharmacology.

Position of SLU-PP-332 among exercise mimetics

Research context and laboratory endpoints

• Pharmacological studies of ERR targets – characterization of new ligands, agonist-profile mapping across ERR alpha, beta and gamma, and SAR analyses.
• Mouse models of endurance and mitochondrial metabolism – treadmill testing, indirect calorimetry, VO2 measurements and muscle-fiber analysis.
• Exercise-mimetic experiments – comparative pharmacology in endurance and mitochondrial-adaptation paradigms.
• Comparisons with other ERR-directed compounds – SLU-PP-332 as a reference pan-agonist in studies of selective ERR alpha or ERR gamma agonists.
• In vitro bioenergetics studies – OCR and ECAR measurements on platforms such as Seahorse in C2C12 cells and hepatocyte cultures.

One Peptides quality specification

• HPLC purity >=98% – high-performance liquid chromatography.
• Structural confirmation by MS – mass spectrometry for each batch.
• Certificate of Analysis (COA) per batch – available to the purchaser.
• Batch traceability – full lot identification.
• Cold chain 2-8 °C – refrigerated transport and storage. After receipt, capsules should be stored in the refrigerator in the original package, protected from light and moisture.
• Stability – SLU-PP-332 powder in capsules is stable when cold-chain conditions are maintained. DMSO working solutions prepared by the researcher should be stored according to standard practice for lipophilic small molecules.

More information about analytical control and documentation is available on the HPLC/COA methodology & batch lookup page.

Working with capsules in a laboratory protocol

Capsule contents can be transferred into a vial under controlled laboratory conditions. As with other low-dose small-molecule reagents, weighing precision, static control, humidity control and proper solvent selection are important.

SLU-PP-332 is discussed as a lipophilic small molecule, so DMSO or other validated solvent systems may be relevant depending on the experimental design. Working solutions should be prepared according to the study protocol, with solvent controls included in cell-culture or animal-model experiments.

All animal work must be approved by the appropriate ethics committee and performed by qualified personnel under local regulations.

Regulatory status and WADA

SLU-PP-332 is a Research Use Only – RUO reagent. It is not registered as a medicine by EMA, FDA, MHRA or other major authorities. It is not a food product, food product or cosmetic ingredient.

The term exercise mimetic may attract sport-related attention, but it does not mean the compound is safe, approved or appropriate for athletes. WADA status can change, and any sport-related interpretation must be checked against the latest WADA-AMA prohibited list. This product is not intended for human use, animal use outside approved research, or performance enhancement.

Related research: metabolic compound research — a guide · BAM-15 mitochondrial uncoupler research (related metabolic compound) · SLU-PP-332 research reagents

FAQ – Frequently Asked Questions

References

1. Wei W et al. (2023). Synthetic ERR alpha/beta/gamma Agonist Induces an ERR alpha-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.
2. Billon C et al. (2024). A Synthetic ERR Agonist Alleviates Metabolic Syndrome.
3. Tian P et al. (2023). Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915.
4. Audet-Walsh E, Giguere V (2015). The multiple universes of estrogen-related receptor alpha and gamma in metabolic control and related diseases.
5. Fan W, Evans R (2015). PPARs and ERRs: molecular mediators of mitochondrial metabolism.